🇺🇸 FDA
Patent

US 11078266

Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3

granted A61PA61P17/00A61P19/02

Quick answer

US patent 11078266 (Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3) held by UNIVERSITÄTSKLINIKUM REGENSBURG expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
UNIVERSITÄTSKLINIKUM REGENSBURG
Grant date
Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P17/00, A61P19/02, A61P21/00, A61P25/00